+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bivalirudin Market by End User, Formulation, Application, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Bivalirudin Market by End User, Formulation, Application, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Bivalirudin Market by End User, Formulation, Application, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083118
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bivalirudin Market grew from USD 1.31 billion in 2024 to USD 1.39 billion in 2025. It is expected to continue growing at a CAGR of 6.16%, reaching USD 1.87 billion by 2030.

Understanding the Bivalirudin Market Landscape

Bivalirudin has emerged as a cornerstone anticoagulant within interventional cardiology, offering a direct mechanism of action that addresses critical safety and efficacy concerns in acute coronary syndrome and percutaneous coronary intervention. Its predictable pharmacokinetics and reduced bleeding risk have elevated it above traditional heparin-based therapies, prompting hospitals and ambulatory centers to reassess protocol standards. As stakeholders navigate evolving clinical guidelines and cost pressures, bivalirudin’s role continues to expand, influencing procurement strategies and patient outcomes.

This executive summary distills pivotal trends and market forces that shape the global bivalirudin landscape. From regulatory shifts and tariff impacts to segmentation nuances and regional performance, each section offers a targeted lens through which decision-makers can refine strategic initiatives. By synthesizing the latest data and expert perspectives, this overview equips manufacturers, healthcare providers, and investors to anticipate market disruptions and optimize growth pathways.

Critical Transformations Reshaping Market Dynamics

The bivalirudin market is undergoing transformative shifts driven by both clinical innovation and healthcare delivery models. Ambulatory surgical centers are rapidly adopting same-day interventional procedures, prompting manufacturers to refine packaging and dosing options that suit outpatient workflows. Simultaneously, hospitals are streamlining anticoagulation protocols, integrating bivalirudin into catheterization laboratory standard operating procedures to enhance patient throughput and safety.

Digital health tools now capture real-time infusion data, enabling clinicians to tailor dosing regimens with unprecedented precision. At the same time, partnerships between pharmaceutical developers and contract manufacturing organizations fuel agile production of both branded and biosimilar formulations. These dynamics converge to reshape supply chains and competitive positioning, underscoring a broader shift toward patient-centric, evidence-driven anticoagulation management.

Assessing the 2025 United States Tariff Implications

In 2025, newly imposed United States tariffs on active pharmaceutical ingredients and finished drug products are poised to elevate manufacturing and distribution costs for bivalirudin. Companies relying on imported peptide synthesis and specialty packaging face margin compression, compelling them to reassess sourcing strategies. Domestic API producers may capture increased demand, yet they must scale operations rapidly to meet volume requirements without compromising quality.

Healthcare systems and group purchasing organizations are responding by renegotiating contracts and exploring alternative anticoagulants. To maintain market share, bivalirudin suppliers must optimize cost-management programs and secure supply chain resilience through dual-sourcing and inventory buffering. Strategic collaboration with raw material vendors and early tariff-adjustment planning will prove decisive in preserving competitive advantage.

Deep Dive into Market Segmentation Frameworks

A multifaceted end user segmentation reveals distinct dynamics between ambulatory surgical centers and hospitals. Ambulatory centers encompass hospital-owned facilities that benefit from integrated supply networks as well as standalone units that prioritize cost-effective purchasing and streamlined inventory management. Hospitals divide into private institutions that often invest in premium anticoagulants to differentiate service offerings and public facilities that balance budget constraints with formulary approvals.

Formulation segmentation underscores the market’s evolving preferences for user-friendly delivery. Lyophilized powder provides stability and extended shelf life, available as ready-to-use presentations or requiring on-site reconstitution by trained pharmacy teams. Prefilled syringes cater to rapid administration needs, featuring either glass barrels valued for inert properties or lightweight plastic barrels that facilitate disposal and reduce breakage risk.

Application segmentation tracks bivalirudin’s primary indications, spanning myocardial infarction, percutaneous coronary intervention and unstable angina cases. Within myocardial infarction, non-ST segment elevation and ST segment-elevation subtypes guide dosing algorithms and hospital protocols. Percutaneous coronary intervention divides into elective procedures, where pre-procedure planning dictates dosage, and emergency interventions that demand immediate, bolus-driven administration.

Route of administration analysis differentiates intravenous bolus protocols from infusion strategies. Intravenous infusion further subdivides into continuous delivery regimens favored for steady anticoagulant levels and intermittent infusion schedules tailored to variable procedural timelines.

Distribution channel segmentation highlights the roles of hospital pharmacies-both in-house compounding labs and third-party managed services-and retail outlets, including regional chain pharmacies with centralized procurement and independent pharmacies that serve niche patient populations.

Regional Variations Driving Growth Patterns

In the Americas, established reimbursement infrastructures and high per capita procedural volumes drive sustained bivalirudin uptake. Stakeholder emphasis on patient safety metrics and value-based care models further supports premium anticoagulant adoption, while regulatory alignment expedites new formulation approvals.

Across Europe, the Middle East and Africa, fragmented regulatory pathways and diverse healthcare funding mechanisms produce variable market entry timelines. Western European countries prioritize clinical outcomes and centralized procurement tenders, whereas emerging EMEA markets hinge on cost-efficacy comparisons and local manufacturing incentives.

In the Asia-Pacific region, rising cardiovascular disease prevalence, expanding hospital networks and growing ambulatory surgery capacity create fertile ground for market growth. Local partnerships and technology transfers accelerate introduction of both branded and generic bivalirudin options, and government initiatives aimed at improving acute cardiac care access underpin long-term demand.

Profiling Leading Players and Competitive Strategies

Global leaders have intensified research and development to fortify their bivalirudin portfolios. A major innovator capitalizes on advanced peptide synthesis to reduce costs, while another diversified manufacturer leverages its broad hospital distribution network to secure formulary placements. A prominent generics company augments its offering with biosimilar equivalents, positioning itself as a low-cost alternative in price-sensitive markets.

Strategic alliances have emerged between pharmaceutical firms and contract development organizations, optimizing scale-up for both lyophilized and prefilled syringe formats. Meanwhile, regional specialists in India and China have invested heavily in API synthesis facilities to serve domestic and export markets. These competitive maneuvers underscore a global race to deliver high-quality, cost-efficient bivalirudin therapies across diverse healthcare environments.

Strategic Recommendations to Capitalize on Emerging Opportunities

Manufacturers should prioritize dual-sourcing strategies and advanced supplier audits to insulate operations from tariff shocks. Investing in modular manufacturing platforms will enable rapid scale-up of both powder and syringe formats, aligning production with evolving end-user needs. Collaborations with ambulatory surgery networks can facilitate pilot programs that demonstrate workflow efficiencies and patient benefits.

Companies must tailor product messaging to reflect regional reimbursement and regulatory landscapes, highlighting clinical and economic value within local contexts. Building partnerships with contract research organizations and digital health vendors will support real-world evidence generation. By integrating data analytics into market access strategies, organizations can refine positioning and accelerate adoption among key opinion leaders.

Rigorous Methodology Underpinning Our Insights

This analysis synthesizes insights from an extensive review of public and proprietary databases, encompassing regulatory filings, hospital procurement records and industry publications. We conducted in-depth interviews with cardiology specialists, pharmacy directors and supply chain executives to capture firsthand perspectives on emerging practice patterns and pain points. Data triangulation coupled with quantitative validation ensures that our findings reflect both macro-level trends and granular operational realities.

Analytical frameworks such as segmentation analysis, competitive benchmarking and risk assessment underpin our conclusions, while peer review by independent industry experts enhances robustness. Acknowledging the dynamic nature of healthcare policy and tariff structures, we have incorporated scenario planning to highlight potential inflection points. This methodology affords stakeholders a balanced, evidence-driven foundation for strategic decision-making.

Synthesizing Insights for a Forward-Looking Outlook

As bivalirudin continues to shape anticoagulation therapy, stakeholders must navigate a landscape defined by evolving delivery models, regulatory shifts and cost pressures. The convergence of ambulatory care expansion, formulation innovation and tariff dynamics presents both challenges and avenues for differentiation. Strategic clarity grounded in granular segmentation and regional analysis will enable manufacturers and providers to capture growing demand while preserving margin integrity.

By aligning operational agility with market intelligence and robust partnerships, organizations are well positioned to realize the full potential of the bivalirudin opportunity. This summary offers the foundational insights necessary to inform corporate strategy, guide resource allocation and foster collaboration across the value chain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Ambulatory Surgical Centers
      • Hospital Owned Ambulatory Surgical Centers
      • Standalone Ambulatory Surgical Centers
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Formulation
    • Lyophilized Powder
      • Powder For Direct Use
      • Powder For Reconstitution
    • Prefilled Syringes
      • Glass Barrel
      • Plastic Barrel
  • Application
    • Myocardial Infarction
      • NSTEMI
      • STEMI
    • Percutaneous Coronary Intervention
      • Elective PCI
      • Emergency PCI
    • Unstable Angina
  • Route Of Administration
    • Intravenous Bolus
    • Intravenous Infusion
      • Continuous Infusion
      • Intermittent Infusion
  • Distribution Channel
    • Hospital Pharmacy
      • In-House Pharmacy
      • Third-Party Managed Pharmacy
    • Retail Pharmacy
      • Chain Retail Pharmacy
      • Independent Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Baxter International Inc.
  • B. Braun Melsungen AG

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bivalirudin Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.2.1. Hospital Owned Ambulatory Surgical Centers
8.2.2. Standalone Ambulatory Surgical Centers
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
9. Bivalirudin Market, by Formulation
9.1. Introduction
9.2. Lyophilized Powder
9.2.1. Powder For Direct Use
9.2.2. Powder For Reconstitution
9.3. Prefilled Syringes
9.3.1. Glass Barrel
9.3.2. Plastic Barrel
10. Bivalirudin Market, by Application
10.1. Introduction
10.2. Myocardial Infarction
10.2.1. NSTEMI
10.2.2. STEMI
10.3. Percutaneous Coronary Intervention
10.3.1. Elective PCI
10.3.2. Emergency PCI
10.4. Unstable Angina
11. Bivalirudin Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous Bolus
11.3. Intravenous Infusion
11.3.1. Continuous Infusion
11.3.2. Intermittent Infusion
12. Bivalirudin Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. In-House Pharmacy
12.2.2. Third-Party Managed Pharmacy
12.3. Retail Pharmacy
12.3.1. Chain Retail Pharmacy
12.3.2. Independent Retail Pharmacy
13. Americas Bivalirudin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Bivalirudin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Bivalirudin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Fresenius Kabi AG
16.3.2. Pfizer Inc.
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.4. Viatris Inc.
16.3.5. Apotex Inc.
16.3.6. Sandoz International GmbH
16.3.7. Baxter International Inc.
16.3.8. B. Braun Melsungen AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIVALIRUDIN MARKET MULTI-CURRENCY
FIGURE 2. BIVALIRUDIN MARKET MULTI-LANGUAGE
FIGURE 3. BIVALIRUDIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL OWNED AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY STANDALONE AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER FOR DIRECT USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER FOR RECONSTITUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIVALIRUDIN MARKET SIZE, BY GLASS BARREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIVALIRUDIN MARKET SIZE, BY PLASTIC BARREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIVALIRUDIN MARKET SIZE, BY NSTEMI, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIVALIRUDIN MARKET SIZE, BY STEMI, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIVALIRUDIN MARKET SIZE, BY ELECTIVE PCI, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIVALIRUDIN MARKET SIZE, BY EMERGENCY PCI, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIVALIRUDIN MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIVALIRUDIN MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIVALIRUDIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIVALIRUDIN MARKET SIZE, BY THIRD-PARTY MANAGED PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIVALIRUDIN MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIVALIRUDIN MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 79. CANADA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 81. CANADA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. CANADA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 83. CANADA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 84. CANADA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 85. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. CANADA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 87. CANADA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 90. CANADA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 164. GERMANY BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. GERMANY BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 167. GERMANY BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. GERMANY BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 169. GERMANY BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 170. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. GERMANY BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 172. GERMANY BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 173. GERMANY BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. GERMANY BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 175. GERMANY BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. GERMANY BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 177. GERMANY BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 183. FRANCE BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 184. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. FRANCE BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 186. FRANCE BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 187. FRANCE BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. FRANCE BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 189. FRANCE BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. FRANCE BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 191. FRANCE BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. ITALY BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ITALY BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 208. ITALY BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. ITALY BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. ITALY BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 211. ITALY BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 212. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. ITALY BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 214. ITALY BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 215. ITALY BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. ITALY BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 217. ITALY BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. ITALY BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 219. ITALY BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 220. SPAIN BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SPAIN BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 223. SPAIN BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 224. SPAIN BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 225. SPAIN BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 226. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. SPAIN BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 228. SPAIN BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 229. SPAIN BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SPAIN BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 231. SPAIN BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. SPAIN BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 233. SPAIN BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. DENMARK BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 280. DENMARK BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 281. DENMARK BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 282. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. DENMARK BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 284. DENMARK BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 285. DENMARK BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. DENMARK BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 287. DENMARK BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. DENMARK BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 289. DENMARK BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 304. QATAR BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. QATAR BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 306. QATAR BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. QATAR BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 308. QATAR BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 309. QATAR BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 310. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. QATAR BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 312. QATAR BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 313. QATAR BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. QATAR BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 315. QATAR BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. QATAR BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 317. QATAR BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 318. FINLAND BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. FINLAND BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 320. FINLAND BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 321. FINLAND BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 322. FINLAND BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 323. FINLAND BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 324. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 325. FINLAND BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 326. FINLAND BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 327. FINLAND BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. FINLAND BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 329. FINLAND BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. FINLAND BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 331. FINLAND BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 337. SWEDEN BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 338. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 339. SWEDEN BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 340. SWEDEN BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 341. SWEDEN BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. SWEDEN BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2030 (USD MILLION)
TABLE 343. SWEDEN BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 344. SWEDEN BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 345. SWEDEN BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 346. NIGERIA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. NIGERIA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 348. NIGERIA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 349. NIGERIA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 350. NIGERIA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2030 (USD MILLION)
TABLE 351. NIGERIA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 352. NIGERIA BIVALIRUDI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Bivalirudin market report include:
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Baxter International Inc.
  • B. Braun Melsungen AG

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.87 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Bivalirudin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Bivalirudin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 85 Pages
  • Global
From
Bivalirudin (CAS 128270-60-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Bivalirudin (CAS 128270-60-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Myocardial Infarction Market Report 2025 - Product Image

Myocardial Infarction Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Bivalirudin Market

Bivalirudin is a cardiovascular drug used to treat and prevent blood clots in patients undergoing coronary angioplasty and other procedures. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme involved in the formation of blood clots. Bivalirudin is administered intravenously and is often used in combination with other anticoagulants. It is also used to treat patients with unstable angina and non-ST-segment elevation myocardial infarction. Bivalirudin is a relatively new drug, having been approved by the U.S. Food and Drug Administration in 2000. It has become increasingly popular in recent years due to its efficacy and safety profile. It is also cost-effective compared to other anticoagulants, making it an attractive option for healthcare providers. Several companies are involved in the bivalirudin market, including AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Merck, and Sanofi. These companies manufacture and market bivalirudin-based products, such as Angiomax and Refludan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.